CEO of Arrowhead Pharmaceuticals Inc (30-Year Financial, Insider Trades) Christopher Richard Anzalone (insider trades) sold 100,000 shares of ARWR on 10/23/2020 at an average price of $58.21 a share. The total sale was $5.8 million.
Arrowhead Pharmaceuticals Inc is a biotechnology company. It is engaged in the development of medicine to treat diseases such as hepatitis B, and thrombosis with a genetic origin, primarily divided by the overproduction of one or more proteins. Arrowhead Pharmaceuticals Inc has a market cap of $6.02 billion; its shares were traded at around $58.88 with and P/S ratio of 47.77. GuruFocus has detected 2 severe warning signs with Arrowhead Pharmaceuticals Inc. .
CEO Recent Trades:
- CEO Christopher Richard Anzalone sold 100,000 shares of ARWR stock on 10/23/2020 at the average price of $58.21. The price of the stock has increased by 1.15% since.
CFO Recent Trades:
- CFO Kenneth Allen Myszkowski sold 29,166 shares of ARWR stock on 10/20/2020 at the average price of $54.04. The price of the stock has increased by 8.96% since.
Directors and Officers Recent Trades:
- Director Mauro Ferrari sold 10,000 shares of ARWR stock on 10/09/2020 at the average price of $48. The price of the stock has increased by 22.67% since.
For the complete insider trading history of ARWR, click here
.This stock alert was generated using automated technology and GuruFocus financial data to provide readers with timely and accurate market reporting. This content was reviewed by GuruFocus editorial team prior to publication. Please send any questions or comments about this story to [email protected].
